Spectrum of Pleiotropic Effects of Statins in Heart Failure

Heart Failure Clinics

Volumn 4, Issue 2, 2008, Pages 153-161

  Mathur, Nitin ^a,b   Ramasubbu, Kumudha ^a,c   Mann, Douglas L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTITHROMBIN III; ATORVASTATIN; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR 5; CERIVASTATIN; COMPACTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FENOFIBRATE; FIBRINOGEN RECEPTOR; FLUINDOSTATIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PITAVASTATIN; PLACEBO; PLASMINOGEN ACTIVATOR; PROTEIN C; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; ROSUVASTATIN; SIMVASTATIN; THROMBOCYTE FACTOR 4; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; LOW DRUG DOSE; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; REVIEW; SECONDARY PREVENTION; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UPREGULATION;

HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; VENTRICULAR REMODELING;

EID: 42149084639     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2008.01.007     Document Type: Review

References (59)

1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33 (1992) 1569-1582
2. Hobbs H.H., Brown M.S., and Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1 (1992) 445-466
3. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002) 285-288
4. Laufs U., and Liao J.K. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 5 (2003) 372-378
5. Edwards P.A., and Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68 (1999) 157-185
6. Martin G., Duez H., Blanquart C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 107 (2001) 1423-1432
7. Li A.C., Binder C.J., Gutierrez A., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114 (2004) 1564-1576
8. Parmar K.M., Nambudiri V., Dai G., et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 280 (2005) 26714-26719
9. Ali F., Hamdulay S.S., Kinderlerer A.R., et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 5 (2007) 2537-2546
10. Seddon M., Looi Y.H., and Shah A.M. Oxidative stress and redox signaling in cardiac hypertrophy and heart failure. Heart 93 (2007) 903-907
11. Maack C., Kartes T., Kilter H., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
12. Chen M.S., Xu F.P., Wang Y.Z., et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 37 (2004) 889-896
13. Plutzky J. Medicine. PPARs as therapeutic targets: reverse cardiology?. Science 302 (2003) 406-407
14. Plutzky J. The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. Am J Cardiol 92 (2003) 34J-41J
15. Kolattukudy P.E., Quach T., Bergese S., et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 152 (1998) 101-111
16. Martínez-González J., Alfón J., Berrozpe M., et al. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 159 (2001) 27-33
17. Domenighetti A.A., Wang Q., Egger M., et al. Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 46 (2005) 426-432
18. Dechend R., Fiebeler A., Park J.K., et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104 (2001) 576-581
19. Diodati J.G., Dakak N., Gilligan D.M., et al. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 98 (1998) 17-24
20. Greer J.J., Kakkar A.K., Elrod J.W., et al. Low-dose simvastatin improves survival and ventricular function via eNOS in congestive heart failure. Am J Physiol Heart Circ Physiol 291 (2006) H2743-H2751
21. Laufs U., Fata V.L., and Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 272 (1997) 31725-31729
22. Laufs U., La Fata V., Plutzky J., et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
23. Saka M., Obata K., Ichihara S., et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 47 (2006) 770-779
24. Mozaffarian D., Minami E., Letterer R.A., et al. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 96 (2005) 1699-1704
25. Tousoulis D., Antoniades C., Vassiliadou C., et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7 (2005) 1126-1132
26. Node K., Fujita M., Kitakaze M., et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
27. Braunwald E. Braunwald's heart disease: a textbook of cardiovascular medicine (2004), Saunders, Philadelphia
28. Blann A.D., Belgore F.M., Constans J., et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 87 (2001) 1160-1163
29. Weis M., Heeschen C., Glassford A.J., et al. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
30. Skaletz-Rorowski A., and Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 14 (2003) 599-603
31. Chong A.Y., and Lip G.Y. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response?. Eur J Heart Fail 9 (2007) 124-128
32. Kearney D., and Fitzgerald D. The anti-thrombotic effects of statins. J Am Coll Cardiol 33 (1999) 1305-1307
33. Bourcier T., and Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 556-562
34. Serebruany V.L., Miller M., Pokov A.N., et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 97 (2006) 1332-1336
35. Serebruany V.L., Midei M.G., Malinin A.I., et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 164 (2004) 2051-2057
36. Malinin A.I., Ong S., Makarov L.M., et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract 60 (2006) 993-1002
37. Ferro D., Basili S., Alessandri C., et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149 (2000) 111-116
38. Bonetti P.O., Lerman L.O., Napoli C., et al. Statin effects beyond lipid lowering: are they clinically relevant?. Eur Heart J 24 (2003) 225-248
39. Kaplan K.L., and Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 57 (1981) 199-202
40. Laufs U., Gertz K., Huang P., et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31 (2000) 2442-2449
41. Haramaki N., Ikeda H., Takenaka K., et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol 27 (2007) 1471-1477
42. Schäfer A., Fraccarollo D., Vogt C., et al. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol 73 (2007) 1367-1375
43. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91 (2005) 27-31
44. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt. J Clin Invest 108 (2001) 391-397
45. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
46. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
47. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9 (2003) 1370-1376
48. Landmesser U., Engberding N., Bahlmann F.H., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004) 1933-1939
49. Brown J.H., Del Re D.P., and Sussman M.A. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 98 (2006) 730-742
50. Lee T.M., Chou T.F., and Tsai C.H. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 40 (2002) 868-874
51. Hattori T., Shimokawa H., Higashi M., et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109 (2004) 2234-2239
52. Kobayashi N., Horinaka S., Mita S., et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 55 (2002) 757-767
53. Martin J., Denver R., Bailey M., et al. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 32 (2005) 697-701
54. Aikawa M., Rabkin E., Sugiyama S., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
55. Zacà V., Rastogi S., Imai M., et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 50 (2007) 551-557
56. Patel R., Nagueh S.F., Tsybouleva N., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 (2001) 317-324
57. Hasegawa H., Yamamoto R., Takano H., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 35 (2003) 953-960
58. Abraham S.S., Osorio J.C., Homma S., et al. Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol 43 (2004) 454-461
59. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., et al. Do statins have an antiarrhythmic activity?. Cardiovasc Res 75 (2007) 10-20